Implications of personalized medicine-perspective from a cancer center
Implications of personalized medicine-perspective from a cancer center
复制标题
DOI：
10.1038/nrclinonc.2010.222
复制
发表时间：
2011-03-01
影响因子：
78.8
通讯作者：
Soria, Jean-Charles
中科院分区：
文献类型：
--
作者：
Tursz, Thomas;Andre, Fabrice;Soria, Jean-Charles
三项进展正在戏剧性地改变肿瘤学的格局。首先，有数百种药物可以抑制与肿瘤发生有关的靶点。其次，对恶性疾病进行重新分类的努力正在扩大孤儿分子疾病的数量。第三，高通量技术的实施将允许复发风险预测和药物敏感性。预计复发的患者将被转介到综合癌症中心，在那里将测试新药。预计将有大量小型生物驱动的临床试验报告对罕见的生物定义疾病的靶向药物高度敏感。需要重新考虑药物注册和生物标记物分析，以避免有对照武器的大型III期试验。高通量技术的使用将导致虚拟细胞的发展。这些考虑突显了发展一个综合性癌症中心联盟的必要性，以便在罕见的、分子定义的人群中进行临床试验，并将高通量技术应用于日常实践。
Three advances are dramatically changing the landscape of oncology. First, hundreds of drugs are available that inhibit targets involved in oncogenesis. Second, efforts to reclassify malignant diseases are expanding the number of orphan molecular diseases. Third, the implementation of high-throughput technologies will allow risk of relapse prediction and drug sensitivity. Patients predicted to relapse will be referred to comprehensive cancer centers where new drugs will be tested. It is anticipated that a high number of small, biology-driven clinical trials will report high sensitivity to targeted agents in rare biologically defined diseases. Drug registration and biomarker analysis needs to be revisited to avoid large phase III trials with control arms. The use of high-throughput technologies will lead to the development of virtual cells. These considerations highlight the need for developing a consortium of comprehensive cancer centers to run clinical trials in rare, molecularly-defined populations, and implement high-throughput technologies for daily practice.